# Kinaset Therapeutics

> Clinical-stage biopharmaceutical company in Medfield, Massachusetts developing novel inhaled
> therapeutics for severe respiratory disease. Lead candidate frevecitinib (KN-002) is a dry-powder
> inhaled pan-JAK inhibitor (JAK1/JAK2/JAK3/TYK2) positioned as a non-invasive anti-inflammatory
> add-on to standard of care for all severe asthma patients, regardless of the underlying cause of
> inflammation, and explored in COPD.

Kinaset Therapeutics does not operate an API. It publishes no developer portal, no public API, no
SDKs, no webhooks, no MCP server, no agent card and no machine-readable API contract (OpenAPI,
AsyncAPI, GraphQL SDL, WSDL or Protobuf). Its product is a clinical drug pipeline, not software.
This file was generated by API Evangelist from the company's public website; it is not published by
Kinaset Therapeutics and should not be read as one.

Agents note: kinasettherapeutics.com runs on Squarespace, and its robots.txt blocks the major AI
crawlers by user agent (including ClaudeBot, GPTBot, anthropic-ai, CCBot, Google-Extended,
Meta-ExternalAgent, Bytespider, Amazonbot and others) and disallows every platform JSON view
(`?format=json`, `?format=json-pretty`, `?format=page-context`, `?format=main-content`,
`?format=ical`). There is no crawl-legal machine-readable surface on this host.

## Company

- [Website](https://www.kinasettherapeutics.com/): Corporate site — company, science, pipeline, partnering and news.
- [About Us](https://www.kinasettherapeutics.com/about-us): Leadership team and board of directors.
- [Science](https://www.kinasettherapeutics.com/science): The inhaled pan-JAK inhibition approach and its rationale in respiratory inflammation.
- [Pipeline](https://www.kinasettherapeutics.com/pipeline): Development-stage programs, led by frevecitinib (KN-002).
- [Partnering](https://www.kinasettherapeutics.com/partnering): Business-development contact for collaboration inquiries.
- [News](https://www.kinasettherapeutics.com/news): Dated press releases from launch (2020) through the Phase 2b PANAIRAMA dosing announcement (July 2026).
- [LinkedIn](https://www.linkedin.com/company/kinaset-tx/): Company profile and updates.
- [Sitemap](https://www.kinasettherapeutics.com/sitemap.xml): 34 URLs — the complete public surface.

## Clinical programs

- frevecitinib (KN-002) — inhaled dry-powder pan-JAK inhibitor for severe asthma; also evaluated in COPD.
- Phase 1/1b: [NCT05006521](https://clinicaltrials.gov/study/NCT05006521) — 49 healthy volunteers plus 55 subjects with mild or moderate-to-severe asthma.
- Phase 2b PANAIRAMA: [NCT07532265](https://clinicaltrials.gov/study/NCT07532265) — first patient dosed July 2026.
- FDA IND clearance for frevecitinib in asthma announced ahead of the Phase 2b program.

## Contact

- info@kinasettx.com
- +1 508-858-5810

## Optional

- [API Evangelist profile](https://apis.io/provider/kinaset-therapeutics/): Independent third-party profile of this company's public API surface — currently recording no API surface.
- [Nasdaq Private Market](https://www.nasdaqprivatemarket.com/): Secondary-market venue where the company's shares have been listed. This is a venue, not a Kinaset property.